Skip to main content

Relmada Therapeutics, Inc.

RLMD
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001553643

In the last 90 days, Relmada Therapeutics, Inc. insiders filed 2 open-market purchases and 0 sales; 126 institutions reported holding it in 13F filings for Q2 2026, worth $693.7M in total; no superinvestor holds it.

13F holders, Q4 2021

Institutional positions in Relmada Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works

Institutional holders
97
+12 vs. Q3 2021
Shares held
20.7M
+10.7M (+107.6%) vs. Q3 2021
Total value
$467.2M
+$205.3M (+78.4%) vs. Q3 2021
New holders
28
27 more added
Sold out
16
24 more reduced

2 institutions that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.

Compare with Q3 2021: new holders, sold out and not filed yet

Holders and value by quarter

Institutions reporting RLMD on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.

Institutional holdersQ4 2021: 97 institutions
Q1 2021: 82 institutionsQ2 2021: 85 institutionsQ3 2021: 87 institutionsQ4 2021: 97 institutionsQ1 2022: 113 institutionsQ2 2022: 113 institutionsQ3 2022: 134 institutionsQ4 2022: 110 institutionsQ1 2023: 91 institutionsQ2 2023: 95 institutionsQ3 2023: 88 institutionsQ4 2023: 83 institutionsQ1 2024: 93 institutionsQ2 2024: 79 institutionsQ3 2024: 69 institutionsQ4 2024: 48 institutionsQ1 2025: 44 institutionsQ2 2025: 50 institutionsQ3 2025: 44 institutionsQ4 2025: 78 institutionsQ1 2026: 103 institutionsQ2 2026: 126 institutions
Value heldQ4 2021: $467.2M
Q1 2021: $335.7MQ2 2021: $318.3MQ3 2021: $262.8MQ4 2021: $467.2MQ1 2022: $623.1MQ2 2022: $468.5MQ3 2022: $953.6MQ4 2022: $66.8MQ1 2023: $40.3MQ2 2023: $39.7MQ3 2023: $45.0MQ4 2023: $56.4MQ1 2024: $66.5MQ2 2024: $40.7MQ3 2024: $40.2MQ4 2024: $4.36MQ1 2025: $1.68MQ2 2025: $3.18MQ3 2025: $15.5MQ4 2025: $245.8MQ1 2026: $588.8MQ2 2026: $693.7M
Institutions holding RLMD and their total value by quarter
QuarterHoldersValue
Q2 2026126$693.7M
Q1 2026103$588.8M
Q4 202578$245.8M
Q3 202544$15.5M
Q2 202550$3.18M
Q1 202544$1.68M
Q4 202448$4.36M
Q3 202469$40.2M
Q2 202479$40.7M
Q1 202493$66.5M
Q4 202383$56.4M
Q3 202388$45.0M
Q2 202395$39.7M
Q1 202391$40.3M
Q4 2022110$66.8M
Q3 2022134$953.6M
Q2 2022113$468.5M
Q1 2022113$623.1M
Q4 202197$467.2M
Q3 202187$262.8M
Q2 202185$318.3M
Q1 202182$335.7M

Institutions, Q4 2021

Shares, value and share of portfolio for each institution holding Relmada Therapeutics, Inc.; share changes are against Q3 2021.

Institutions holding RLMD in Q4 2021
InstitutionSharesValue% of portfolioChange in sharesAction
State of Wisconsin Investment Board0$00.00%−20,100−100.0%Sold out
Parametric Portfolio Associates LLC0$00.00%−18,117−100.0%Sold out
Jump Financial, LLC0$00.00%−16,900−100.0%Sold out
Belvedere Trading LLC0$00.00%−10,699−100.0%Sold out
Manufacturers Life Insurance Company, The0$00.00%−8,407−100.0%Sold out
Price T Rowe Associates Inc0$00.00%−8,057−100.0%Sold out
DekaBank Deutsche Girozentrale0$00.00%−5,000−100.0%Sold out
Group One Trading, L.P.0$00.00%−2,035−100.0%Sold out
Penserra Capital Management LLC0$00.00%−400−100.0%Sold out
Parallel Advisors, LLC0$00.00%−184−100.0%Sold out
Glen Eagle Advisors, LLC0$00.00%−25−100.0%Sold out
Retirement Group, LLC0$00.00%−5−100.0%Sold out
State of Wyoming0$00.00%−5−100.0%Sold out
Spotlight Asset Group, Inc.––––Not filed
Knott David M––––Not filed